Results 11 to 20 of about 4,009 (198)

CD138 (syndecan-1) expression in health and disease. [PDF]

open access: yesHistology and histopathology, 2014
CD138 (syndecan-1, Sdc-1) is a member of the syndecan family that comprises heparan sulfate proteoglycans. CD138 is significant for cell-cell and cell-matrix interactions. In adult human tissues, CD138 is predominantly expressed in epithelial cells and plasmacytes.
Palaiologou, Marina   +2 more
core   +7 more sources

Splenic B-1a Cells Expressing CD138 Spontaneously Secrete Large Amounts of Immunoglobulin in Naïve Mice [PDF]

open access: yesFrontiers in Immunology, 2014
B-1a cells constitutively secrete natural antibody that provides immediate protection against microbial pathogens and functions homeostatically to speed removal of apoptotic cell debris.
Nichol E Holodick   +2 more
doaj   +2 more sources

CD10 and CD138 can be expressed in giant cell tumor of bone: An immunohistochemical study

open access: yesAvicenna Journal of Medicine, 2016
Giant cell tumor of bone (GCTB) is a primary bone neoplasm which is characterized by the presence of mononuclear cells (MCs) and osteoclast-like multinucleated giant cells (MNGCs).
Mousa A Al-Abbadi   +5 more
doaj   +2 more sources

Profilin 1 induces drug resistance by downregulating CD138 expression via autophagy in multiple myeloma

open access: yesDiscover Oncology
Multiple myeloma (MM), a plasma cell-derived malignant hematological disease, is often treated with bortezomib, a highly effective first-generation proteasome inhibitor. However, resistance to bortezomib is a common occurrence.
Ya Wang   +4 more
doaj   +2 more sources

CD138 as a Specific CSF Biomarker of Multiple Sclerosis

open access: yesNeurology Neuroimmunology & Neuroinflammation
The aim of this study was to identify novel biomarkers for multiple sclerosis (MS) diagnosis and prognosis, addressing the critical need for specific and prognostically valuable markers in the field.We conducted an extensive proteomic investigation, combining analysis of (1) CSF proteome from symptomatic controls, fast and slow converters after ...
Hinsinger, Geoffrey   +15 more
openaire   +4 more sources

La inmunohistoquímica CD138 identifica más células plasmáticas en comparación con tinción hematoxilina-eosina en hepatitis autoinmune. Un estudio observacional

open access: yesRevista de Gastroenterología de México
Resumen: Introducción: La hepatitis autoinmune (HAI) está asociada con infiltración periportal de células plasmáticas. La detección de células plasmáticas se realiza rutinariamente por medio de tinción hematoxilina-eosina (HE).
A.F. Romano-Munive   +4 more
doaj   +2 more sources

Efficacy of endometrial microbiota testing-guided personalized therapy in infertile women stratified by CD138 status: a retrospective cohort study

open access: yesFrontiers in Endocrinology
BackgroundChronic endometritis (CE) is a persistent inflammatory condition of the endometrium associated with infertility. Current diagnosis relies on histopathological markers like CD138, which may not fully assess the functional state of the ...
Fang He   +10 more
doaj   +2 more sources

Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus

open access: yesFrontiers in Immunology, 2020
CD138 (syndecan 1), a member of the heparan-sulfate proteoglycan family, regulates diverse biological responses by interacting with chemokines, cytokines, growth factors, and adhesion molecules.
Lunhua Liu   +2 more
doaj   +1 more source

Macrophage Inhibitory Factor-1 (MIF-1) controls the plasticity of multiple myeloma tumor cells. [PDF]

open access: yesPLoS ONE, 2018
Multiple Myeloma (MM) is the second most common hematological malignancy with a median survival of 5-10 years. While current treatments initially cause remission, relapse almost always occurs, leading to the hypothesis that a chemotherapy-resistant ...
Danielle Joseph   +2 more
doaj   +1 more source

Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma model [PDF]

open access: yesLeukemia, 2012
Tumor-initiating capacity of CD138− and CD138+ tumor cells in the 5T33 multiple myeloma ...
Van Valckenborgh, Els   +12 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy